WVP
PCRX icon

Worth Venture Partners’s Pacira BioSciences PCRX Stock Holding History

Worth Venture Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,200
Closed -$4K – 129
2017
Q4 		$4K Buy
+3,200
New +$127K ﹤0.01% 103

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Worth Venture Partners's PCRX Position: Q1 2018 in Review

Worth Venture Partners sold out of Pacira BioSciences (PCRX) in Q1 2018, closing a stake of 9,557 shares — an estimated $436K sold.

Worth Venture Partners first reported a position in PCRX in Q4 2017 and held it in 1 quarter. The position peaked at $436K in Q4 2017. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

  • Worth Venture Partners reported no remaining Pacira BioSciences position as of Q1 2018 after selling out during the quarter.
  • Worth Venture Partners sold 9,557 Pacira BioSciences shares in Q1 2018, an estimated $436K.
  • Worth Venture Partners first reported a position in Pacira BioSciences in Q4 2017 and held it in 1 quarter.
  • Worth Venture Partners's Pacira BioSciences position peaked at $436K in Q4 2017.
  • 168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on Worth Venture Partners's 13F filing for Q1 2018, filed 11 May 2018.